Ireland: Life Sciences, Biotechnology & Nanotechnology

The text remains subject to formal endorsement by both institutions and to legal-linguistic revision before adoption, with publication in the Official Journal expected ahead of the original...

This report examines how deal activity in the life sciences and healthcare sector performed during 2025, highlighting key trends, significant transactions and emerging themes shaping the market. The report also looks ahead to 2026, considering the factors likely to influence M&A activity in Ireland in the year ahead.

There is no doubt that the Network and Information Security Directive (EU) 2022/2555 (“NIS 2”) significantly raises the bar for cybersecurity requirements in the EU.

On 11 December 2025, the Council of the European Union (the “Council”) and the European Parliament (the “Parliament”) provisionally reached an agreement on the first major reform of EU pharmaceutical rules since 2004. The agreement (known as the “Pharma Package”) aims to increase patients’ access to medicinal products across the EU and to boost the competitiveness of the pharmaceutical industry.

The long-awaited revision of the EU pharmaceutical legislation has reached a significant milestone: agreement was secured on 11 December 2025 at the trilogue stage...

The EU and UK have recently introduced several legislative changes which update the existing statutory regime on product liability and safety.

As the European Union (EU) continues its digital health transformation, the European Medicines Agency (EMA) and the Heads of Medicines Agencies...

On 5 May 2025, the European Commission released an updated version of the Manufacturer...

On 17 June a major milestone was reached in terms of the proposals to revise the EU general pharmaceutical legislation, with trilogue negotiations getting underway.